Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
GlobeNewswire, Inc.
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and...
New Memoranda pave the way for €50 million in investments in local development and public health
Government of Slovenia
SLOVENIA, May 18 - The Memoranda were signed by His Excellency Vegard Kaale, Ambassador of the Kingdom of Norway, Her Excellency Helga Hauksdóttir, Ambassador of Iceland, representing the Donor States, i.e., the Kingdom of Norway, the Principality...
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
GlobeNewswire, Inc.
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner
GlobeNewswire, Inc.
Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO Capital Tetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals, appointed as Venture Partner London, United...
St. Kitts and Nevis enters New Space through historic life sciences mission with Switzerland
EIN Presswire
Caribbean–Swiss partnership launches space biology experiment to advance STEM education, research capacity, and international collaboration.
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
GlobeNewswire, Inc.
Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and older First European...
Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy
EIN Presswire
LONDON, UNITED KINGDOM, June 9, 2025 /EINPresswire.com/ -- The Principality of Liechtenstein continues to demonstrate its exceptional standing on the global stage, with two recent developments underscoring its strength in both financial...
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
GlobeNewswire, Inc.
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...
Virella Files European Patent Application for Novel SIRT6 Small-Molecule Activators
EIN Presswire
Liechtenstein-based biotech company reports significant lifespan extension in C. elegans and advances toward preclinical development with CRO partners SCHAAN, LIECHTENSTEIN, April 3, 2026 /EINPresswire.com/ -- Virella Ltd, a European biotech...
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
GlobeNewswire, Inc.
First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025 RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and...
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
GlobeNewswire, Inc.
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda® (tovorafenib) represents a rare achievement that reinforces the urgent...
CEO Insight’s Investors Guide Examines Evolving Investment Strategies Across Global Financial Markets
EIN Presswire
Featuring senior industry voices, the issue explores cross-border investment, financial innovation and the growing importance of trust in global markets.
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
GlobeNewswire, Inc.
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based on Phase II/III clinical data...
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
GlobeNewswire, Inc.
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected...
Dental Laboratories Market Set to Reach USD 13.09 Billion by 2030 | MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL, March 30, 2026 (GLOBE NEWSWIRE) -- The global dental laboratories market, valued at US$8.66 billion in 2024, stood at US$9.20 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2024 to 2030, culminating...
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
GlobeNewswire, Inc.
REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and...
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
EIN Presswire
PerioCream, a mucoadhesive formulation based on NitrAdine®, has been granted a certification as a Class IIa medical device according to MDR (EU) 2017/745 bonyf NV (ENX:MLBON) KNOKKE-HEIST, KNOKKE-HEIST, BELGIUM, October 16, 2025...
bonyf – A Year of Certification, Innovation and Commercial Acceleration
EIN Presswire
update on the year 2025 which has been a decisive period for bonyf, marked by regulatory achievements, sustained innovation and accelerating commercial momentum bonyf NV (ENX:MLBON) KNOKKE-HEIST, KNOKKE-HEIST, BELGIUM, January 28, 2026...
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
GlobeNewswire, Inc.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
CEO Insight Releases New 2026 Issue Examining Trust, Governance and Global Connectivity
EIN Presswire
LONDON, UNITED KINGDOM, January 19, 2026 /EINPresswire.com/ -- CEO Insight has released its Q1 2026 issue, offering senior executives, investors and policymakers an in-depth examination of how jurisdictions are competing for capital, credibility...
Sign up for:
Health Monitor Liechtenstein
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.